AccuImage names National Sales and Marketing Manager.

SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Aug. 7, 1998-- AccuImage Diagnostics Corporation (OTC-BB:AIDP) today announced the appointment of Shelley Staggs as their National Sales and Marketing Manager.

Staggs has 15 years of experience in medical sales to hospitals, and previous to her current appointment, was Siemens Product Manager for CT and MRI medical imaging devices with a solid customer base in eight western states -- California, Nevada, Oregon, Washington, Idaho, Montana, Alaska, and Hawaii. Staggs earned her B.S. in Radiologic Technology from the Univ. of Oklahoma (1983) and holds a National ARRT license as well as being a certified radiological technologist (Texas license).

According to Dr. Allen Poirson, President and CEO, "We are very fortunate to have acquired such an accomplished salesperson in medical devices who also has outstanding clinical and computer expertise. Staggs is the ideal person to build and manage a national sales force of individuals who can sell this state-of-the-art equipment." The success of AccuImage in providing enabling solutions for Imatron Inc. (NASDAQ:IMAT) EBT scanner users is a model that should apply to the medical scanner market as a whole. (On Feb 23 and March 5, the two companies announced that Imatron would provide world-wide sales, service, and support services for AccuImage workstations.)

AccuImage is a public company based in South San Francisco primarily engaged in design, development, and marketing of high-speed 2D, 3D and 4D image processing software used for medical image visualization on the Internet and hospital Intranets. 4-D refers to the capability of displaying a 3-D object in motion such as the beating heart. AccuImage workstations process images obtained from Ultrafast CT(R) scanners, standard CT scanners, MRI scanners, and Ultrasound scanners that are connected to standard hospital networks using the DICOM standard.

AccuImage workstations are installed at leading hospitals and clinics internationally, including the University of California-San Francisco, UCLA, Mayo Clinic, Stanford University, University of Munich, Singapore National University, Youngsei Hospital, University of Graz, HeartScan USA, HeartScan South Africa, and others.

Except for the historical information contained herein, the matters discussed in this news release may contain forward-looking statements that are based on current expectations and estimates about the industries in which Imatron and AccuImage operate, the estimated impact of certain technological advances, the estimated impact of published research studies on scanner sales and procedures, as well as management's beliefs and assumptions.

It is important to note that these companies' actual results could differ materially from those projected in such forward-looking statements.

The factors that could cause actual results to differ materially include, among others: failed clinical demonstration of certain asserted technological advantages and diagnostic capabilities; reliance on product distributors; competition in the diagnostic imaging market; failure to improve product reliability or introduce new product models and enhancements; delays in production and difficulty in obtaining components and sub-assemblies from limited sources of supply; inability to meet cash-on-delivery or prepayment terms from vendors; determinations by regulatory and administrative government authorities; patent expiration and denial of patent applications; the high cost of the scanner as compared to commercially available CT scanners; and the risk factors listed from time to time in the companies' Securities and Exchange Commission reports, including their reports on Form 10-K for their current fiscal year.

    CONTACT:  AccuImage Diagnostics Corp.
               Chris Shepherd, 650/875-0192
               [e-mail]
               http://www.accuimage.com